ReviewMolecules (Basel, Switzerland)2025
Modern Developing Directions in the Dihydroquercetin Study.
Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- Selective Hydrogenation of Quercetin to Dihydroquercetin Using a Carbon Nanotube-Supported Non-Noble Nickel Catalyst.ACS omega · 2026Article
- Taxifolin Attenuates Remote Lung Injury Induced by Hepatic Ischemia-Reperfusion in Rats.Molecules (Basel, Switzerland) · 2026Article
- 2R,3R-trans-Dihydroquercetin Has Powerful Antioxidant Properties, Prevents DNA and Protein Damage, and Protects Mice from Injury Caused by Radiation-Induced Oxidative Stress.Antioxidants (Basel, Switzerland) · 2026Article
- Dihydroquercetin in Obesity and Prediabetes: Case Report and Insights from Molecular Modeling.International journal of molecular sciences · 2026Article
- Molecular Mechanism of Dihydroquercetin in Ameliorating Metabolic Dysfunction-Associated Steatotic Liver Disease: Insights Into the HIF-1α/VEGF Pathway.Food science & nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dihydroquercetin (taxifolin) is a natural bioflavonoid with diverse biological activities, including antioxidant, anti-inflammatory, antibacterial, antiviral, and geroprotective effects. The review summarizes current advances in the research of dihydroquercetin with a focus on its structural features, physicochemical properties, and biological functions. Particular attention is drawn to its low solubility and limited bioavailability, which have stimulated the development of nanotechnology-based delivery systems. In the paper, the systematization of the systems, namely nanoparticles, liposomes, hydrogels, nanofibers, nanoenzymes, and crystalline complexes, is presented. Moreover, some specific features of the antibacterial and antiviral action of the compound are described. Recent findings on the molecular mechanisms of action, including regulation of oxidative stress and cellular signaling pathways, highlight the therapeutic promise of dihydroquercetin. Taken together, the data support its potential as a valuable compound for pharmaceutical and biomedical applications, though further comprehensive investigations are required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.